Literature DB >> 17438862

Validation of HPLC method for determination of atorvastatin in tablets and for monitoring stability in solid phase.

Beata Stanisz1, Lukasz Kania.   

Abstract

A rapid high performance liquid chromatographic method was developed and validated for determination of atorvastatin in pharmaceutical dosage forms, and for evaluation of its stability in the solid phase. Separation of atorvastatin was successfully achieved on a C-18 column utilizing water--acetonitrile at the volumetric ratio of 48:52, adjusted to pH 2.0 with 80% ortho-phosphoric acid. The detection wavelength was 245 nm. The method was validated and the response was found to be linear in the drug concentration range of 0.04 mg/mL - 0.4 mg/mL. The mean values +/- RSD of the slope and the correlation coefficient were 8.192 +/- 0.260 and 0.999, respectively. The RSD values for intra- and interday precision were < 1.00% and 0.90%, respectively. The degradation kinetic of atorvastatin at 363 K in a relative humidity of 76.4% was observed to be autocatalytic first order reaction. The kinetic parameters were as follows: k (where k represents the velocity constant; s(-1)) = (1.42 +/- 0.19) 10(-6); t(0.5) (where t(0.5) represents the time needed for a 50% decay of atorvastatin; days) = 32.82 +/- 0.9; t(0.1) (where t(0.1) represents the time needed for a 10% decay of atorvastatin; days) = 13.86 +/- 0.8.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17438862

Source DB:  PubMed          Journal:  Acta Pol Pharm        ISSN: 0001-6837            Impact factor:   0.330


  7 in total

1.  Effect of AGTR1 and BDKRB2 gene polymorphisms on atorvastatin metabolism in a Mexican population.

Authors:  Sarahí Herrera-González; Denisse Aideé Martínez-Treviño; Marcelino Aguirre-Garza; Magdalena Gómez-Silva; Hugo Alberto Barrera-Saldaña; Rafael Baltazar Reyes León-Cachón
Journal:  Biomed Rep       Date:  2017-10-25

2.  A validated densitometric method for analysis of atorvastatin calcium and metoprolol tartarate as bulk drugs and in combined capsule dosage forms.

Authors:  Sm Patole; As Khodke; Lv Potale; Mc Damle
Journal:  J Young Pharm       Date:  2011-01

3.  A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.

Authors:  Rafael B R León-Cachón; Jorge A Ascacio-Martínez; María E Gamino-Peña; Ricardo M Cerda-Flores; Irene Meester; Hugo L Gallardo-Blanco; Magdalena Gómez-Silva; Everardo Piñeyro-Garza; Hugo A Barrera-Saldaña
Journal:  BMC Cancer       Date:  2016-02-08       Impact factor: 4.430

4.  Two spectrophotometric methods for simultaneous determination of some antihyperlipidemic drugs.

Authors:  Nada S Abdelwahab; Badr A El-Zeiny; Salwa I Tohamy
Journal:  J Pharm Anal       Date:  2012-02-21

5.  Design and Characterization of Atorvastatin Dry Powder Formulation as a potential Lung Cancer Treatment.

Authors:  Alaa S Tulbah; Amr Gamal
Journal:  Saudi Pharm J       Date:  2021-11-11       Impact factor: 4.330

6.  Validated spectrophotometric methods for the simultaneous determination of telmisartan and atorvastatin in bulk and tablets.

Authors:  Kaliappan Ilango; Pushpangadhan S Shiji Kumar
Journal:  Pharm Methods       Date:  2012-07

7.  Optimized zein nanospheres for improved oral bioavailability of atorvastatin.

Authors:  Fahima M Hashem; Majid M Al-Sawahli; Mohamed Nasr; Osama A A Ahmed
Journal:  Int J Nanomedicine       Date:  2015-06-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.